CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shaperon Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shaperon Inc
Phone: +82 260838315p:+82 260838315 SEOUL, 06373  South Korea Ticker: 378800378800

Business Summary
Shaperon Inc is a Korea-based company mainly engaged in the biopharmaceutical business. The Company is engaged in the research, development (R&D), manufacture and sale of pneumonia therapy, alzheimer's disease therapy and atopic therapy as well as other medicines.
(Source: N-30D)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chief Executive Officer, Director Seung YongSung 57 12/31/2022

General Information
Number of Employees: 44 (As of 6/30/2023)
Outstanding Shares: 23,071,031 (As of 12/31/2023)
Shareholders: 12,727
Stock Exchange: KDQ
Fax Number: +82 260838318


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024